Answers are grounded in this paper and cite their sources.
The global increase in drug-resistant fungal infections poses an important threat to public health, with conventional antifungal agents facing drawbacks in efficacy, toxicity, and resistance development. This systematic review explores the ability of nanotechnology-based antifungal strategies to address these issues by evaluating 14 experimental studies published between 2014 and 2024. A broad range of nanomaterials, including copper, zinc, silver, selenium, and silica-based nanoparticles, was assessed for their antifungal properties against clinically relevant pathogens such as Candida albicans , Aspergillus spp., and Fusarium . These nanomaterials exhibited potent antifungal activity through reactive oxygen species generation, membrane disruption, enzyme inhibition, and biofilm suppression. Some formulations incorporated advanced delivery features, including stimulus-responsive release and enhanced bioavailability. Green synthesis approaches, using plant- or marine-derived organisms, presented the eco-friendly potential for nanoparticle fabrication. Despite promising in vitro efficacy and broad-spectrum activity, key translational challenges remain. These include a lack of in vivo validation, concerns about toxicity and nanoparticle stability, formulation complexity, and limited scalability. The findings suggest that nanotechnology provides a powerful and adaptable platform to mitigate antifungal resistance. However, future success lies in comprehensive preclinical evaluations, standardized testing protocols, and regulatory frameworks to harness clinical translation. This review emphasizes the urgent need for interdisciplinary collaboration to realize the therapeutic potential of nanotechnology in mitigating drug-resistant fungal infections.
No takes yet. Share an insight, caveat, or question.
Oso et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: